Compare IRTC & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRTC | IBRX |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | 673 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.1B |
| IPO Year | 2016 | N/A |
| Metric | IRTC | IBRX |
|---|---|---|
| Price | $155.27 | $5.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $217.31 | $11.80 |
| AVG Volume (30 Days) | 606.2K | ★ 47.6M |
| Earning Date | 02-19-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $702,573,000.00 | $82,555,000.00 |
| Revenue This Year | $27.42 | $680.06 |
| Revenue Next Year | $17.05 | $90.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 25.45 | ★ 1025.95 |
| 52 Week Low | $92.52 | $1.83 |
| 52 Week High | $212.00 | $8.28 |
| Indicator | IRTC | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.31 | 69.72 |
| Support Level | $158.90 | $5.71 |
| Resistance Level | $174.36 | $8.28 |
| Average True Range (ATR) | 8.77 | 0.71 |
| MACD | -1.68 | 0.31 |
| Stochastic Oscillator | 12.35 | 60.58 |
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.